Drug profile · INN
arformoterol tartrate
ARFORMOTEROL TARTRATE
arformoterol tartrate (ARFORMOTEROL TARTRATE) is a beta-2 adrenergic receptor agonist. Associated with Teva Pharma GmbH. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — arformoterol tartrate
- US status
- approved
- Class
- —
- Route
- INHALATION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
arformoterol tartrate (ARFORMOTEROL TARTRATE) is a beta-2 adrenergic receptor agonist. Associated with Teva Pharma GmbH. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-2 adrenergic receptor agonist
Primary target: Beta-2 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is arformoterol tartrate?
arformoterol tartrate (ARFORMOTEROL TARTRATE) is a beta-2 adrenergic receptor agonist. Associated with Teva Pharma GmbH. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for arformoterol tartrate?
ARFORMOTEROL TARTRATE is a marketed brand name for arformoterol tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of arformoterol tartrate?
arformoterol tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.